ATH 11.1% 0.5¢ alterity therapeutics limited

Any news ??, up in NY 8%, page-14

  1. 115 Posts.
    lightbulb Created with Sketch. 54

    @pierre77

    Phase 2 trials to begin enrollment in the 2nd half of 2021. That has been announced at least twice, the first time being when they announced the Michael J Fox Foundation grant. The whole purpose of the BioMUSE study was to guide the design of the Phase 2 trials. So once the Phase 2 trials start the BioMUSE study is irrelevant in that regard.

    I can't remember which announcement it was, but they were also looking at extending the BioMUSE study to run in parallel with the Phase 2 study, but I have not seen anything to suggest that is going to happen. This would presumably be to help with the design of Phase 3 trials.

    So my original statement is in fact correct, and not misleading.

    And perhaps you should pay more attention, you spelt my name wrong!!!
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.001(11.1%)
Mkt cap ! $26.22M
Open High Low Value Volume
0.4¢ 0.5¢ 0.4¢ $14.25K 2.930M

Buyers (Bids)

No. Vol. Price($)
66 81346070 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 19609447 23
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.